HRA Pharma Offloads Commercial Rights To Uterine Fibroid Therapy In U.S. And Canada
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty pharma PregLem gains rights to develop and sell ulipristal acetate for benign gynecological disorders in U.S. and Canada.